Findings Highlight Unmet Medical Need in Cancer Patients with Class II and Class III BRAF Alterations Who May Not Have Access to Approved Targeted Therapies
SAN FRANCISCO and SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) — Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for treat genomically defined cancers, today announced the presentation of the results of a collaborative study with Tempus investigating the prevalence of Class II and Class III alterations in patients with BRAF-mutated solid tumors. These results were presented as an e-poster at the Virtual Congress on Targeted Cancer Therapies (TAT) of the European Society for Medical Oncology (ESMO), taking place March 7-9, 2022.
“Advances in genomic profiling have greatly increased our ability to define emerging patient populations and have enabled the development of effective targeted therapies for patients who do not currently benefit from precision medicine approaches,” said Richard Williams, MBBS , Ph.D., Chief Medical Officer at Kinnate. “Through our collaboration with Tempus and other leading precision medicine companies, we have found that there are a significant number of cancer patients with Class II or Class III BRAF alterations, none of whom have access to approved targeted cancer therapies. We appreciate the opportunity to share information about this urgent unmet need with the clinical research community gathered for the ESMO TAT 2022 conference.”
This study used an anonymized clinicogenomic database of over 55,000 cancer patients whose tumors were profiled using the Tempus xT next-generation sequencing assay, a 648-gene paired DNA panel to RNA transcriptome sequencing. A cohort of more than 1,100 patients has been identified with BRAF class II or class III oncogenic alterations representing approximately 2% of patients. Among patients with class II or class III BRAF alterations, those diagnosed with melanoma or non-small cell lung cancer (NSCLC) were most often treated with immunotherapy or chemotherapy +/- immunotherapy, respectively. At least 70% of patients with BRAF alterations had stage IV (metastatic) disease, and the cancer stage distribution was similar across all BRAF classes. Compared to BRAF class I alterations, BRAF class II and class III alterations were more likely to coexist with other genetic alterations in the MAPK pathway such as NRAS, KRAS, and NF1. Within the NSCLC and melanoma cohort, tumors with class II or class III BRAF alterations had a higher tumor mutation burden (TMB) than wild-type BRAF tumors. Additionally, patients with NSCLC and Class II or Class III alterations experienced a shorter time to treatment discontinuation in first and second line treatment compared to patients with NSCLC and Class I BRAF alterations, suggesting inferior treatment outcomes.
“These results are particularly interesting given that BRAF Class II and Class III alterations are prevalent oncogenic drivers without approved targeted therapy. Tumors with BRAF Class II or Class III alterations have been shown to be associated with unique tumor characteristics, including higher BMR and more frequent co-occurrence with other MAPK pathway alterations Our study of real-world data indicates that patients with NSCLC and BRAF class II alterations or class III experience a shorter time to discontinuation compared to patients with NSCLC and class I BRAF alterations,” said Paul Severson, Ph.D., senior director of Translational Medicine and Bioinformatics at Kinnate.
The e-Poster (Presentation #40P), entitled “Real-world clinical genomic analysis of patients with BRAF-mutant cancers identifies BRAF classes II and III as a population of unmet medical needwill be presented by Dr. Severson and is available to registered participants for on-demand viewing at: www.esmo.org/meetings/esmo-tat-2022.
Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapies by developing products designed to address significant unmet needs. Kinnate uses its deep expertise in structure-based drug discovery, translational research and patient-focused precision medicine, which it calls the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, Kinnate’s team is comprised of drug discovery experts supported by a distinguished group of scientific advisors. For more information, please visit www.kinnate.com.
This press release contains forward-looking statements that involve substantial risks and uncertainties. These forward-looking statements include, but are not limited to, statements regarding the potential benefits of our product candidates and statements from our employees. Words such as “believes”, “anticipates”, “plans”, “expects”, “intends”, “will”, “target”, “potential” and similar expressions are also intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections regarding future events and trends. These expectations and projections may never materialize or may prove to be incorrect. These forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors, including risks associated with the recent transition to operating as a clinical-stage biopharmaceutical company with a history of limited exploitation; our ability to raise additional capital to fund our operations; our ability to discover, advance preclinical and clinical development, obtain regulatory approval and commercialize our product candidates; the new approach we are taking to drug discovery and development; our ability to timely file and obtain approval of investigational new drug applications for our planned clinical trials; the possibility that the results of clinical trials will differ from the results of our preclinical studies; adverse impacts of the COVID-19 pandemic on our business, including ongoing and planned clinical trials and ongoing and planned preclinical studies; competition in our industry; regulatory developments in the United States and other countries; our ability to attract, hire and retain senior executives and highly qualified employees; difficulties in managing our growth; our ability to protect our intellectual property; the use of third parties to conduct our preclinical studies and any ongoing or planned future clinical trials, and to manufacture our product candidates; general economic and market conditions; and other risks. These and other risks, uncertainties, assumptions and other factors are described in more detail under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 which we have filed with the Securities and Exchange Commission (the “SEC”), as well as in our subsequent filings made by us with the SEC. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, or to assess the impact of all factors on our business or the extent to which any one factor, or a combination of factors, could cause actual results to differ materially from those contained or implied by the forward-looking statements. Investors should not rely on forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Our forward-looking statements speak only as of the date of this release, and except as required by law, we undertake no obligation to publicly update any forward-looking statements for any reason in the future.